Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...
Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...
Scilex宣佈與FDA成功舉行了第二階段會議的結束，達成一致前進到新藥申請(NDA)的路徑，完成第三階段試驗，用於治療...
Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of Chronic Neck Pain Associated With Muscle Spasms
Scilex宣佈與FDA成功舉行了第二階段會議的結束，達成一致前進到新藥申請(NDA)的路徑，完成第三階段試驗，用於治療慢性頸部疼痛伴隨肌肉痙攣的爆款產品候選SP-103(利多卡因局部系統) 5.4%
資訊熱榜
更新時間